Print

Data on Navidea Biopharmaceuticals (NEOP)’s AZD4694 Presented by the Banner Alzheimer's Institute at the 6th Annual Human Amyloid Imaging Meeting (HAI)  
1/20/2012 6:29:55 AM

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE Amex: NAVB) today announced that the Banner Alzheimer’s Institute, Phoenix, AZ, made two presentations of results from an AstraZeneca-sponsored study on the assessment of Navidea’s late-stage radiopharmaceutical imaging candidate, AZD4694, at the 6th Annual Human Amyloid Imaging Meeting (HAI), in Miami, FL. In December 2011, Navidea in-licensed the worldwide exclusive rights to AZD4694 from AstraZeneca, now being developed by Navidea as a radiopharmaceutical agent for the detection of cerebral amyloid in Alzheimer’s disease (AD) patients.
//-->